Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Juni 2012 08:30 ET | Quelle: Lumos Pharma, Inc.

NewLink Genetics Reports Two- and Three-Year Overall Survival Data From Its Phase-2 HyperAcute(R) Pancreas (algenpantucel-L) Immunotherapy Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

AMES, Iowa, June 4, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) announces that its HyperAcute® Pancreas (algenpantucel-L) Immunotherapy will be featured today in a poster...
01. Juni 2012 09:00 ET | Quelle: Lumos Pharma, Inc.

Data From an Investigator-Initiated Phase 2 Study of NewLink Genetics' HyperAcute(R) Melanoma Immunotherapy Published in 2012 ASCO Annual Meeting Abstracts

AMES, Iowa, June 1, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced results from a Phase 2 investigator-initiated study of NewLink's HyperAcute® Melanoma...
30. Mai 2012 08:01 ET | Quelle: Lumos Pharma, Inc.

NewLink Genetics to Present at the Jefferies 2012 Global Healthcare Conference

AMES, Iowa, May 30, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that Dr. Charles Link, Chairman and Chief Executive Officer, will present at the Jefferies 2012 Global...
22. Mai 2012 09:00 ET | Quelle: Lumos Pharma, Inc.

Data From NewLink Genetics Phase 2 Trial of Its HyperAcute(R) Pancreas (Algenpantucel-L) Immunotherapy to be Presented at the 2012 Digestive Disease Week

AMES, Iowa, May 22, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), today announced that Phase 2 data from its investigational HyperAcute® Pancreas immunotherapy clinical...
10. Mai 2012 17:00 ET | Quelle: Lumos Pharma, Inc.

NewLink Genetics Corporation Reports First Quarter 2012 Financial Results

AMES, Iowa, May 10, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today...
24. April 2012 08:00 ET | Quelle: Lumos Pharma, Inc.

NewLink Genetics Receives Notice of Allowance From USPTO for New Patent Broadly Covering Its D-1MT IDO Pathway Inhibitor

AMES, Iowa, April 24, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that the United States Patent & Trademark Office (USPTO) has allowed broad claims to oral...
17. April 2012 08:00 ET | Quelle: Lumos Pharma, Inc.

NewLink Genetics Receives Notice of Allowance From the Japan Patent Office for New Patent Broadly Covering Its HyperAcute(R) Cancer Immunotherapy Products

AMES, Iowa, April 17, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that the Japan Patent Office has issued a notice of allowance for a patent entitled "Antitumor...
13. April 2012 12:31 ET | Quelle: Lumos Pharma, Inc.

NewLink Genetics and Its CEO Are Recognized as High-Tech Leaders by the Technology Association of Iowa

AMES, Iowa, April 13, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), today announced that NewLink and its Chief Executive Officer, Dr. Charles Link, each received one of the 2012...
11. April 2012 07:00 ET | Quelle: Lumos Pharma, Inc.

NewLink Genetics to Present Data at the American Society of Clinical Oncology and Digestive Disease Week Annual Meetings

AMES, Iowa, April 11, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that data from its HyperAcute® Pancreas immunotherapy and its HyperAcute® Lung...
29. März 2012 08:00 ET | Quelle: Lumos Pharma, Inc.

NewLink Genetics Corporation Reports Fourth Quarter and Full-Year 2011 Financial Results

AMES, Iowa, March 29, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today...

Vorherige Seite

Nächste Seite